香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* ( 於百慕達註冊成立之有限公司 ) (股份代號：00512) 於二零二五年四月十日舉行之股東週年大會之 投票表決結果 茲提述遠大醫藥集團有限公司 (「本公司」) 於二零二五年三月十九日發出之通函 (「通函」) 及所有於股東週年大會通告 (「通告」) 中提呈之決議案。於本公佈內所用 之釋義，除文義另有所指外，將與該通函所定之意義相同。 表決結果 董事會宣佈，於二零二五年四月十日舉行之股東週年大會中，所有提呈之決議案均以投 票方式獲正式通過。 - 主席兼執行董事唐緯坤博士及行政總裁兼執行董事周超先生親身出席； - 執行董事楊光先生及林芷伊女士，非執行董事蘇彩雲女士，邢麗娜博士及胡野碧先 生均透過電話形式出席；及 - 非執行董事裴更博士因其他公務而缺席股東週年大會。 於股東週年大會當日，本公司之已發行股份數目為 3,5 ...

EF001 免責聲明 EF001 發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 董事會由四名執行董事唐緯坤博士、周超先生、楊光先生及林芷伊女士；及四名獨立非執行董事蘇彩雲女士、邢麗娜博士、胡野碧 先生及裴更博士組成。 第 2 頁 共 2 頁 v 1.1.1 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 遠大醫藥集團有限公司 | | 股份代號 | 00512 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至二零二四年十二月三十一日止年度之末期股息 | | 公告日期 | 2025年3月12日 | | 公告狀態 | 更新公告 | | 更新/撤回理由 | 更改派發日 | | 股息信息 | | | 股息類型 | 末期 ...

中金报告指出，远大医药2024年纯利同比增长31.3%至24.7亿港元，超出预期，主要得益于核药销售超 预期和Telix股权投资收益。 校对：祝甜婷 核药板块高速增长，RDC管线预计2025年开始贡献收益，传统板块保持稳健。 公司STC3141脓毒症临床结果预计2025年上半年公布。 中金上调远大医药目标价33.3%至7.2港元，维持"跑赢行业"评级，维持2025年每股盈利预测0.6港元，并 预计2026年每股盈利0.63港元。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* ( 於百慕達註冊成立之有限公司 (股份代號：00512) 自願性公告 此外，本集團於二零二四年十二月獲得中華人民共和國國家藥品監督管理局「( 藥監局」) 批准在中國開展另一項 ITM-11 的 III 期臨床試驗（「COMPETE 橋接試驗」），旨 在評估 ITM-11 多肽受體放射性核素治療（PRRT）對比標準治療，在不可手術、進 展性、高分化 1 級或 2 級、SSTR+的 GEP-NETs 患者中的有效性和安全性。海外研 究方面，ITM SE 開展的 COMPETE III 期臨床試驗於二零二五年一月成功達到了主 要臨床終點，這也將會為中國的 COMPETE 橋接試驗提供積極的數據支持。這兩項 III 期臨床試驗將有助於 ITM-11 產品對於 GEP-NETs 各階段病程的全方位覆蓋。 本集團於 2024 ...

Core Viewpoint - CICC maintains a "outperform" rating for Yuan Da Pharmaceutical (00512) and raises the target price by 33.3% to HKD 7.2 [1] Financial Performance - The company reported a net profit of HKD 2.47 billion, a year-on-year increase of 31.3%, exceeding CICC's expectations [1] - The growth was primarily driven by higher-than-expected nuclear medicine volume and gains from Telix equity investments [1] Earnings Forecast - CICC maintains the earnings per share (EPS) forecast for this year at HKD 0.6 and introduces a new EPS forecast of HKD 0.63 for 2026 [1] Business Segments - The nuclear medicine segment is experiencing rapid growth, with the RDC pipeline expected to start generating revenue in 2025 [1] - The traditional business segment remains stable, with attention on the clinical results of STC3141 for sepsis, with preliminary results expected in the first half of this year [1]

此乃要件 請即處理 閣下如對本通函之任何內容或應採取之行動有任何疑問，應諮詢 閣下之股票經紀或其 他註冊證券交易商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已售出或轉讓名下所有遠大醫藥集團有限公司股份，應立即將本通函及隨附之代 表委任表格送交買主或承讓人，或經手買賣或轉讓之銀行、股票經紀或其他代理商，以 便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不會就本通函全部或任何部分內容而 產生或因依賴該等內容而引致之任何損失承擔任何責任。 GRAND PHARMACEUTICAL GROUP LIMITED 遠 大 醫 藥 集 團 有 限 公 司* （ 於 百 慕 達 註 冊 成 立 之 有 限 公 司 ） （股份代號：00512） (1) 購回股份及發行新股份之一般授權； (2) 重選退任董事； 及 (3) 股東週年大會通告 遠大醫藥集團有限公司謹訂於二零二五年四月十日（星期四）上午十一時正假座香港皇后 大道中99號中環中心3302室舉行股東週年大會或其任何續會，股東週年大會通告載於本 通函第13至17頁。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本通告全部或任何部分內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （ 於 百 慕 達 註 冊 成 立 之 有 限 公 司 ） （股份代號：00512） 股東週年大會通告 茲通告遠大醫藥集團有限公司（「本公司」）謹訂於二零二五年四月十日（星期四）上午十一 時正假座香港皇后大道中99號中環中心3302室舉行股東週年大會（「股東週年大會」），以 便處理下列事項： — 1 — 1. 採納截至二零二四年十二月三十一日止年度之經審核財務報表及董事會報告書與核 數師報告書。 2. 宣派截至二零二四年十二月三十一日止年度末期股息每股港幣0.26元。 3. (a) 重選楊光先生為本公司執行董事； (b) 重選林芷伊女士為本公司執行董事； (c) 重選邢麗娜博士為本公司獨立非執行董事；及 (d) 授權董事會釐定本公司董事之酬金。 4. 重聘國衛會計師事務所有限公司為核數師，任期直至下屆股東週年大會結束為止， 並授權董事會釐定其酬金。 作為特別事項，考慮及酌情通過下列決議案為普通決議案（不論 ...

主席致辭 03 | 01 築基 | | | --- | --- | | 責任引領，行穩致遠 | | | 完善企業管治 | 12 | | 強化 ESG 治理 | 13 | | 利益相關方參與 | 15 | | 重大性議題矩陣 | 17 | | 商業道德 | 19 | | 風險管理 | 23 | | 信息安全及隱私保護 | 27 | 目錄 環境、社會及管治報告 關於本報告 02 | 03 堅守 | | | --- | --- | | 質量至上，守護健康 | | | 質量管理 | 44 | | 臨床倫理 | 50 | | 藥物警戒 | 52 | | 責任營銷 | 55 | | 04 | | --- | | 惜才 | | 攜手員工，共赴成長 | 06 共繪 同舟共濟，共築美好 | 供應鏈管理與發展 | 94 | | --- | --- | | 行業共建 | 100 | | 回饋社會 | 102 | 05 健康環境，綠色共榮 76 84 87 89 | 104 | 附錄一： | | --- | --- | | | 關鍵績效表 | 58 62 67 71 人才多元與包容 人才培訓與發展 人才保留與關愛 職業健康與安全 0 ...

Industry Growth and Market Potential - In 2024, China's pharmaceutical manufacturing industry saw a year-on-year growth of 3.6% in industrial added value above designated size, although this was lower than the overall industrial growth rate[6]. - The Chinese market for radiopharmaceuticals is projected to reach RMB 9.3 billion by 2025, with a compound annual growth rate (CAGR) of 22.7% from 2025 to 2030[9]. - The innovative ophthalmic drug market in China is expected to grow to RMB 44 billion by 2025 and RMB 116.6 billion by 2030, with a CAGR of approximately 19.8%[11]. - The pharmaceutical industry in China is expected to experience strong growth driven by policy reforms and globalization, with increased demand for innovative drugs[13]. Strategic Acquisitions and Partnerships - The company successfully completed strategic acquisitions, including 100% stakes in Tianjin Tanabe Pharmaceutical Co., Nanchang Baiji Pharmaceutical Co., and Jiangxi Bai'an Baiyu Pharmaceutical Technology Co., significantly expanding its presence in cardiovascular and respiratory fields[8]. - The group acquired 100% of Tianjin Tanabe for approximately RMB 486 million, entering the chronic disease market and expanding its cardiovascular product portfolio[31]. - The group purchased 100% of Baiji Pharmaceutical for about RMB 260 million, becoming one of the companies with the most comprehensive product pipeline for allergic rhinitis in China[31]. - The company has established strategic partnerships and collaborations, including with Telix Pharmaceutical Limited, enhancing its product pipeline in the nuclear medicine field[9]. - A strategic cooperation agreement has been reached with Jixing Pharmaceutical Hong Kong Co., Ltd. for the exclusive development and commercialization rights of the innovative nasal spray products OC-01 and OC-02 in the Greater China region[28]. Research and Development Initiatives - The company has 147 ongoing research and development projects with an investment of approximately HKD 2.27 billion[21]. - 63 significant milestones were achieved in the R&D efforts during the year[21]. - The R&D portfolio consists of 47 innovative projects, accounting for 32% of the total, and 100 generic and other projects, making up 68%[23]. - The company is focusing on innovation in nuclear medicine, respiratory and critical care, ophthalmology, and cardiovascular precision intervention[15]. - The company plans to enhance its R&D capabilities through collaboration with leading medical institutions domestically and internationally[15]. Financial Performance - The company's revenue for the year ended December 31, 2024, reached HKD 11,644,892, representing a 10.6% increase from HKD 10,529,590 in 2023[40]. - The profit before tax for 2024 was HKD 2,852,363, up from HKD 2,344,197 in 2023, indicating a growth of 21.7%[40]. - Net profit attributable to shareholders for 2024 was HKD 2,466,059, a 30% increase compared to HKD 1,895,442 in 2023[40]. - Total assets as of December 31, 2024, amounted to HKD 24,991,165, an increase from HKD 22,515,326 in 2023, reflecting a growth of 11.0%[42]. - The company achieved a compound annual growth rate (CAGR) of 12% in revenue from 2020 to 2024[45]. Product Development and Innovations - The company introduced innovative products, including a unique eye formulation for treating Demodex blepharitis and a new mechanism nasal spray for treating dry eye syndrome, enhancing its portfolio in the ophthalmology sector[8]. - The innovative product STC3141 for severe diseases has successfully completed all patient enrollments in Phase II clinical trials in China[12]. - The global innovative ophthalmic drug GPN01768 (TP-03, Loteprednol Etabonate eye drops, 0.25%) has submitted a New Drug Application (NDA) to the regulatory authority and received acceptance[28]. - The innovative drug GPN00833 for postoperative inflammation and pain has received FDA approval in March 2024 and has shown significant statistical differences in anti-inflammatory and analgesic effects compared to the control group in clinical trials[116]. - The company has launched 14 new commercialized products in 2024, including innovative products in oncology and cardiovascular intervention sectors[49]. Market Expansion and Globalization - The international sales network covers over 140 countries and regions, with overseas business accounting for more than 40% of total sales[141]. - The company is expanding its R&D capabilities with multiple platforms globally, including a focus on mRNA technology for anti-tumor and anti-infection drugs[156]. - The company has accelerated its globalization efforts, with over 320 employees overseas and 8 clinical approvals in the US, Australia, Belgium, Poland, and the UK[164]. Regulatory Approvals and Clinical Trials - The global innovative RDC drug ITM-11 for treating gastroenteropancreatic neuroendocrine tumors has received formal approval for a Phase III clinical study (COMPETE bridging trial) in China[27]. - The global innovative temperature-sensitive embolic agent GPN00289 has completed the first patient enrollment in a registration clinical study for primary liver cancer transarterial chemoembolization in China[28]. - The NDA application for the global innovative drug Ryaltris® nasal spray for allergic rhinitis has been accepted by the drug regulatory authority[31]. - The company has submitted Investigational New Drug (IND) applications for two Phase III clinical trials for ITM-11, targeting gastroenteropancreatic neuroendocrine tumors (GEP-NETs), which have been approved by the regulatory authority[51]. Corporate Governance and Sustainability - The company is actively pursuing ESG initiatives, promoting green pharmaceutical practices and enhancing access to quality medical resources[12]. - The group is committed to environmental sustainability through initiatives like water conservation and recycling[187]. - The group has established long-term relationships with suppliers, ensuring compliance with quality and ethical standards[190]. Challenges and Legal Matters - The company has been involved in several lawsuits related to product quality issues, with a total compensation of approximately RMB 40,199,645.99 paid as a result of 75 court judgments as of December 31, 2024[171]. - The company has successfully recovered RMB 10,000,000 from a previous equity transfer agreement and is pursuing an additional RMB 11,228,044.48 from the seller due to unmet performance commitments[172].

(Incorporated in Bermuda with limited liability) ( 於百慕達註冊成立之有限公司 ) (Stock Code 股份代號: 00512) 各位非登記股東： 遠大醫藥集團有限公司*（「本公司」）- 可供查閱通知 - 年度報告及通函（「本次公司通訊」）的刊發通知 本公司的本次公司通訊備有中、英文版本，並已上載於本公司網站 www.grandpharma.com 及香港交易所披露易（「披露易」）網站 www.hkexnews.hk，歡迎瀏覽。 若 閣下已選擇收取本公司的公司通訊（「公司通訊」） （附註） 之印刷本，則隨函附奉 閣下所選擇之本次公司通訊印刷本。 閣下若因任何 理由以致在收取或接收載於本公司網站上的本次公司通訊出現困難，本公司將於接到 閣下通知後，盡快向 閣下免費發送有關本次 公司通訊的印刷本； 閣下可以書面方式通知本公司的香港股份過戶登記處（「股份過戶處」）香港中央證券登記有限公司，地址為香 港灣仔皇后大道東 183 號合和中心 17M 樓，或電郵至 grandpharma.ecom@computershare.com.hk。 閣下有權要求更改所選擇收取日 ...